Results 151 to 160 of about 19,166 (184)
Some of the next articles are maybe not open access.
A New “Inhibitor” of Complement (C5)-Derived Chemotactic Activity
The Journal of Immunology, 1978Abstract In the course of examining polymorphonuclear leukocyte (PMN) chemotaxis in patients with systemic lupus erythematosus (SLE), we have found a previously undescribed serum “inhibitor” of complement (C5)-derived chemotactic activity.
H Daniel Perez +3 more
openaire +1 more source
The clinical potential of Affibody-based inhibitors of C5 for therapeutic complement disruption
Expert Review of Proteomics, 2016The awareness of the complement system as an important target area for therapeutic intervention has increased over the last decade, primarily due to the successful introduction of the C5 inhibiting...
Magnus M, Berglund, Patrik, Strömberg
openaire +2 more sources
Complement C5-inhibitor rEV576 (coversin) ameliorates in-vivo effects of antiphospholipid antibodies
Lupus, 2014Activation of the complement cascade is an important mechanism for antiphospholipid antibody-mediated thrombosis. We examined the effects of rEV576 (coversin), a recombinant protein inhibitor of complement factor 5 activation, on antiphospholipid antibody-mediated tissue factor up-regulation and thrombosis.
Z, Romay-Penabad +7 more
openaire +2 more sources
Complement Inhibitors Targeting C3, C4, and C5
2000Activation of the complement system (Fig. 1) is the key to the development of normal inflammatory responses against foreign pathogens. During the course of this activation process a number of biological events are initiated, including generation of small peptides that induce local inflammatory responses, tagging of foreign pathogens with complement ...
Arvind Sahu +2 more
openaire +1 more source
Expert Opinion on Biological Therapy, 2005
Myocardial injury and dysfunction in acute infarction and during cardiac surgery with cardiopulmonary bypass (CPB) are associated with an undesirable systemic inflammatory response, in which the complement cascade plays a major role. In animal models C5 inhibition has been found to significantly reduce myocardial infarct size and decrease cellular ...
Ani J, Fleisig, Edward D, Verrier
openaire +2 more sources
Myocardial injury and dysfunction in acute infarction and during cardiac surgery with cardiopulmonary bypass (CPB) are associated with an undesirable systemic inflammatory response, in which the complement cascade plays a major role. In animal models C5 inhibition has been found to significantly reduce myocardial infarct size and decrease cellular ...
Ani J, Fleisig, Edward D, Verrier
openaire +2 more sources
Nephron
Complement-mediated thrombotic microangiopathy (CM-TMA) is a rare and life-threatening complication that can occur in kidney transplant recipients, with various potential triggers including immunosuppressive medications. The optimal management and duration of treatment with C5 inhibitors (C5i) for CM-TMA in this patient population remain areas of ...
Pilar Musalem +4 more
openaire +2 more sources
Complement-mediated thrombotic microangiopathy (CM-TMA) is a rare and life-threatening complication that can occur in kidney transplant recipients, with various potential triggers including immunosuppressive medications. The optimal management and duration of treatment with C5 inhibitors (C5i) for CM-TMA in this patient population remain areas of ...
Pilar Musalem +4 more
openaire +2 more sources
Journal of clinical & laboratory immunology, 1981
Serum levels of 13 individual complement component and control proteins were measured in 25 male cigarette smokers and 25 male non-smokers. A significant elevation of the mean serum levels of C5, C9 and C1-inhibitor was demonstrated for the smokers while levels of C1q, C2, C4, C3, C6, C8, Factor B, properdin, C3b inactivator and beta 1H did not differ ...
R J, Wyatt, R B, Bridges, D G, Halatek
openaire +1 more source
Serum levels of 13 individual complement component and control proteins were measured in 25 male cigarette smokers and 25 male non-smokers. A significant elevation of the mean serum levels of C5, C9 and C1-inhibitor was demonstrated for the smokers while levels of C1q, C2, C4, C3, C6, C8, Factor B, properdin, C3b inactivator and beta 1H did not differ ...
R J, Wyatt, R B, Bridges, D G, Halatek
openaire +1 more source
Pozelimab/cemdisiran. Complement protein C5 inhibitor, Treatment of complement-mediated diseases
Drugs of the Future, 2023openaire +1 more source
CLINICAL DEVELOPMENT OF THE C5 COMPLEMENT INHIBITOR, PEXELIZUMAB
Shock, 2004openaire +1 more source